N/A N=35 Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training for Incomplete Spinal Cord Injury Patients
Spinal Cord Injuries
Primary: Gait Speed With 10-Meter Walk Test — -10.24; -1.79 seconds — p=0.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=155 The Pivotal Study of the Aptus Endovascular AAA Repair System
Abdominal Aortic Aneurysms (AAA)
Primary: Effectiveness: Composite Success Rate — 4 participants
Phase 3 N=1,296 A Phase 3 Study in Participants With Moderate to Severe Psoriasis
Psoriasis
Primary: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure…
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 4 N=280 A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine
Migraine Disorders
Primary: Percentage of Patients With Adverse Events — 24.37 Percentage of Patients
N/A N=40 Closed-Loop Fluid Administration System Using Hemodynamic Monitors
Intraoperative Volume Status · Postoperative Complications
Primary: Fluid Status During Surgery — 95 percentage of case time
Phase 1 N=82 An Open Label Dose Escalation Study Of E7080
Solid Tumor or Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 25 milligram (mg)
N/A N=28 Bioequivalence Study for Mejoral 500 Product
Pain
Primary: Area Under the Curve From Time Zero to Last Sampling Time [AUC(0-t)] — 15.212; 14.698 hours*microgram/millilitre (h*μg/mL)
N/A N=2,600 Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Post-ERCP Pancreatitis — 47; 100 participants
Phase 3 N=236 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Phase 2 N=40 A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) — 255 days
N/A N=68 Functional Vision With ACRYSOF® IQ IOLs Blue Light Filtration
Cataract
Primary: Change in Braking Reaction Time From No-glare to Glare — 0.07; 0.15 seconds
Phase 3 N=143 Open-Label Lesinurad Monotherapy Extension Study in Gout
Gout
Primary: Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL — 68 Subjects
Phase 3 N=324 Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Tophaceous Gout
Primary: Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6 — 0.566; 0.761; 0.468 Proportion of Subjects — p=0.1298
N/A N=19 Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®
Myopia
Primary: Conjunctival Staining - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A — 0.42; 0.53; 0.68; 0.47 units on a scale